The use of optimum conventional growth hormone administration, using a growth hormone vial combined with an Auto Injector, was compared with a pen injection system using a cartridge of growth hormone. In both methods of administration the concentration of growth hormone was 16 IU/ml. Thirty patients (22 boys, eight girls) who had all previously been treated with growth hormone (4 IU/ml) administered using needles and syringes (without an Auto Injector) were randomised into receiving one of either treatment for three months and then crossed over for a further three months. Fourteen patients (10 boys, four girls) initialiy received KabiVial 16
viously been treated with growth hormone (4 IU/ml) administered using needles and syringes (without an Auto Injector) were randomised into receiving one of either treatment for three months and then crossed over for a further three months. Fourteen patients (10 boys, four girls) initialiy received KabiVial 16 IU/ml combined with an Auto Injector while 16 patients (12 boys, four girls) were treated with KabiPen 16 IU/ml. Mean age in both groups was 9-6 years. The majority of patients in both groups were treated with a regimen of either 15 or 20 units/m2/week as a daily subcutaneous injection. Of the 30 patients who started in this trial, two who commenced using an Auto Injector refused to change to a pen system and were excluded from further analysis. When scored on a scale of -5 to +5 general convenience when changing from an Auto Injector to the KabiPen decreased from +4-7 to +1-0. When assessed for pain, the Auto Injector group scored +4-7, which decreased to -0-2 (more painful) for the pen. At the end of the trial 23 patients (82%) chose to continue with the KabiVial/Auto Injector combination as they found this less painful and the child did not see the needle or need to insert the needle manually. Five patients (18%) continued with the KabiPen as they considered the device smaller and easier to use. The accuracy of dosing using KabiVial was 100% compared with the range of 88% to 111% using KabiPen as the latter was available only in 0-5 unit increments. No growth hormone was wasted using KabiVial, although a mean of 0-6 units was wasted with every 16 IU cartridge in the KabiPen system.
It is concluded that patients should be able to contribute to the choice of growth hormone delivery systems and that newer methods need careful assessment. Biosynthetic human growth hormone has traditionally been administered using a powdered growth hormone preparation in a vial to which diluent is added before the resulting solution is drawn up into a smaller syringe before injection. This is a relatively inconvenient form of preparation. Kabi Pharmacia have developed a new range of convenience products which are superior in that the growth hormone powder and water are present in the same applicator and are mixed by closing a syringe barrel (fig 1) . Administration is by either needles and syringes or as a cartridge in a pen injection system.' Both of these new formulations of biosynthetic human growth hormone (Genotropin) are prepared in an identical concentration of 16 IU/ml.
Previous trials of a pen injection system against conventional application by needles and syringes have been biased because the volume of injection has been unequal when comparing the two systems,'-3 which may be of particular significance when assessing pain. Although a pen injection system may offer a significant improvement in convenience, the patient still has manually to insert the needle subcutaneously. However, pen injection systems have not been evaluated against optimum treatment using an Auto Injector (which uses a 1 ml syringe and needle), a spring loaded device which automatically inserts the needle subcutaneously and delivers the injection. pituitary hormone deficiency (n=3), hypopituitarism after cranial irradiation (n=4), and dysmorphic syndromes (n= 5). One of the latter children had Ehler-Danlos syndrome with easy bruising as part of his symptoms. Growth hormone in all the patients was administered by needles and syringes and none had previously used a pen injection system or an Auto Injector. All patients were selected by receiving a dose regimen of under 4 IU per day (the maximum dose which can be administered by KabiPen). After obtaining parental consent to participate in this study, patients were randomised to either three months of growth hormone administered by a pen injection system (KabiPen) or using KabiVial in combination with an Auto Injector (Owen Mumford Ltd). Mean age in the two groups was 9-7 years (range 3-313-7) in one group and 9-6 years (range 51-16 6) in the other. Sex distribution was similar in the two groups: 14 patients (10 boys, four girls) and 16 patients (12 boys, four girls) respectively. Surface area was similar in both groups: 1-0 m2 (range 0-5-1-8) and 0 95 m2 (range 0 6-1 5).
After a three month period all patients completed a questionnaire and then changed to a further three months of treatment with the alternative method of administration and completed a further questionnaire. These were completed in the presence of a growth research nurse (GH) and both pain of injection and general convenience were rated on a scale of -5 to +5. At the end of the six month period the children were allowed to continue with whichever treatment method they preferred.
Growth hormone administration was calculated as a weekly total dose related to surface area and divided equally into seven daily subcutaneous injections. The dose regimen of growth hormone administration was similar in both groups: the majority received either 15 IU/ m2/week (n=4 in both groups) or 20 IU/iM2 week (n=7 in both groups). A few patients received higher dose regimens of 25 or 30 IU/ m2/week but were similarly distributed in both treatment groups. The daily dose of growth hormone was calculated and allocated to the closest 0 5 unit increment available when using the pen system, and the difference in dose allocation between KabiVial fig 2. When scored for general convenience, changing from the Auto Injector to the KabiPen, the score decreased from +4-7 to +1-0 (p<0-001) and when scored for pain the decrease was from +4 0 to -0-2 (p<0-001).
The accuracy of dosage administration was 100% using KabiVial whereas the range of dose variation was between 88% and 111% using KabiPen, which relates to the fixed 0-5 unit increments between dose schedules. No wastage of growth hormone occurred using KabiVial as at the end of the vial the remaining growth hormone was topped up using a new vial. However using the pen cartridge system the mean quantity of growth hormone remaining at the end of the cartridge was 0-6 units (range 0-I0). 
Discussion
Our results suggest that the older m growth hormone treatment using a syi combined with an Auto Injector is supi pen injection system both when assesst patients for convenience and pain as w dosage considerations. The predominai tage for compliance was due to t Injector's ability both to insert the ne administer the injection rapidly with ti out of sight of the child and this advan greatly appreciated by the children. I we would suggest that in children difficulties with compliance it would b able to use an Auto Injector rather th injection system. However a few chil prefer the KabiPen (five out of 28 because the device was small and ther noise associated with its use. The scoring indicated that the KabiPen may acceptable if it is used as the initial m growth hormone administration. It is in that the majority of children continu the pen injector system gave their own i whereas only 50% of those continuing Auto Injector self administered. Earlie have suggested that a pen injection sy: superior to using needles and syringes. have not combined treatment using Injector to optimise conventional treati have compared applicators using diffe: centrations of growth hormone. It is un. that although the KabiPen injection s supplied free of charge to the patients, does not apply to an Auto Injector. patients found the technique ofobtainin hormone in solution considerably sim more convenient using both Kabi1 KabiPen than older growth hormone n vials.
All the patients involved in this study were taught by an experienced growth research nurse. Certainly this may well account for the increased number of children administering their own injections during the study. Unfortunately, from the nature of the applicators involved, it was not possible to make this a double blind study. Our study was designed to take into account the limitations of the maximum dose of Ito Injector KabiPen of 4 units per day, which severely restricts the use of this device in pharmacological regimens of growth hormone treatment, especially high dose growth hormone regimens used in girls with Turner's syndrome.5 In addition this accounted for why we had a younger mean age group of patients than would have been otherwise expected, which may bias the study further. For reasons of convenience, growth hormone treatment was only injected once daily and this led to a residue of growth hormone in the KabiPen cartridge whereas there was no corresponding waste using a vial. Of course, ;tor there is the possibility of using different dosages of growth hormone on different days of the le baseline week in order to avoid wastage but this would and imply a complicated regimen that may be counterproductive in terms of compliance.
Certainly the most important decision ofwhich applicator to use, in terms of convenience, should be made by the child/parent. Although growth hormone from a vial combined with an iethod of Auto Injector may be more complicated to preringe but pare, the simplicity and passivity of the injec-)erior to a tion technique outweighs the advantages of a ed by the pen injector system. Additionally, in terms of vell as for dosage consideration, a vial is more accurate ntadvan-and less wasteful of expensive resources. Of he Auto course the KabiPen injection system would be zedle and improved if doses greater than 4 units could be he needle administered and if dose increments were ntage was acceptable in less than 0-5 units. It is unlikely Certainly that more than one growth hormone injection n having per day6 is necessary to optimise growth )e prefer-response and so the convenience of a relatively ian a pen portable pen device becomes minimal, in conldren did trast to the experience of an insulin pen injec-1) mainly tion system in the treatment of diabetes re was no mellitus. Great care should be taken in advising patients' patients about injection techniques and we y be more recommend that children/parents are shown the nethod of alternative methods available and then they are iteresting able to make their own choice. This may well be Ling with of great significance for compliance to growth injections hormone treatment, which is probably far worse g with an than had previously been appreciated (S L er studies Smith The results are encouraging, the effect on seizure control being 'good' in 33% and 'worthwhile' in 56%. It might be expected that callostomy would benefit most those with seizures of focal origin with secondary generalisation and there was some evidence in this series that this was so but significant benefit was also seen in apparently primarily generalised epilepsy. Only six of the 43 patients were of normal intelligence and many were severely retarded. Improvement after operation occurred at all levels of intelligence. Small increases in measured IQ were found in those whose epilepsy improved. Of particular interest to paediatricians is the finding that eight of 14 patients with the Lennox-Gastaut syndrome gained significant benefit from the operation.
The apparent success of this operation poses considerable logistic problems. Neurosurgeons with a specific interest in epilepsy surgery are few, as are centres with the appropriate staffing and facilities for assessment of these patients but patients who might be considered for surgery are many. The implications for the organisation of services for children with epilepsy are potentially very great. 
